Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Guigal-Stephan, N; Lockhart, B; Moser, T; Heitzer, E.
A perspective review on the systematic implementation of ctDNA in phase I clinical trial drug development.
J Exp Clin Cancer Res. 2025; 44(1):79
Doi: 10.1186/s13046-025-03328-4
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Heitzer Ellen
- Co-Autor*innen der Med Uni Graz
- Moser Tina
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Circulating tumour DNA (ctDNA) represents an increasingly important biomarker for the screening, diagnosis and management of patients in clinical practice in advanced/metastatic disease across multiple cancer types. In this context, ctDNA-based comprehensive genomic profiling is now available for patient management decisions, and several ctDNA-based companion diagnostic assays have been approved by regulatory agencies. However, although the assessment of ctDNA levels in Phase II-III drug development is now gathering momentum, it remains somewhat surprisingly limited in the early Phase I phases in light of the potential opportunities provided by such analysis. In this perspective review, we investigate the potential and hurdles of applying ctDNA testing for the inclusion and monitoring of patients in phase 1 clinical trials. This will enable more informed decisions regarding patient inclusion, dose optimization, and proof-of-mechanism of drug biological activity and molecular response, thereby supporting the evolving oncology drug development paradigm. Furthermore, we will highlight the use of cost-efficient, agnostic genome-wide techniques (such as low-pass whole genome sequencing and fragmentomics) and methylation-based methods to facilitate a more systematic integration of ctDNA in early clinical trial settings.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Circulating Tumor DNA - genetics, blood
- Drug Development - methods
- Clinical Trials, Phase I as Topic - administration & dosage
- Neoplasms - drug therapy, genetics
- Biomarkers, Tumor - genetics
- Find related publications in this database (Keywords)
- Circulating tumour DNA (ctDNA)
- Phase I trial
- Pharmacodynamics
- Pharmacokinetics
- Molecular response
- RECIST
- Tumour fraction